Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 14 | 2024 | 901 | 3.150 |
Why?
|
| Mohs Surgery | 10 | 2024 | 40 | 2.900 |
Why?
|
| SEER Program | 2 | 2024 | 211 | 1.540 |
Why?
|
| Dermatologic Surgical Procedures | 3 | 2024 | 35 | 1.390 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 32 | 1.130 |
Why?
|
| Nose | 3 | 2023 | 114 | 1.060 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2019 | 16 | 1.000 |
Why?
|
| Rhinoplasty | 2 | 2023 | 54 | 0.870 |
Why?
|
| Paget Disease, Extramammary | 1 | 2024 | 5 | 0.850 |
Why?
|
| Nail Diseases | 2 | 2015 | 15 | 0.850 |
Why?
|
| Surgical Flaps | 3 | 2024 | 180 | 0.830 |
Why?
|
| Dermatofibrosarcoma | 1 | 2024 | 17 | 0.820 |
Why?
|
| Skin Transplantation | 2 | 2013 | 56 | 0.780 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 140 | 0.730 |
Why?
|
| Counseling | 1 | 2023 | 237 | 0.710 |
Why?
|
| Skin | 2 | 2018 | 543 | 0.700 |
Why?
|
| Lidocaine | 2 | 2024 | 39 | 0.690 |
Why?
|
| Anesthetics, Local | 2 | 2024 | 86 | 0.640 |
Why?
|
| Cicatrix | 2 | 2012 | 125 | 0.630 |
Why?
|
| Acrospiroma | 1 | 2019 | 4 | 0.600 |
Why?
|
| Facial Neoplasms | 1 | 2019 | 23 | 0.590 |
Why?
|
| Bandages | 2 | 2024 | 52 | 0.580 |
Why?
|
| Fissure in Ano | 1 | 2018 | 6 | 0.560 |
Why?
|
| Vulvar Diseases | 1 | 2018 | 13 | 0.560 |
Why?
|
| Infliximab | 1 | 2018 | 63 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 754 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 114 | 0.510 |
Why?
|
| Alternariosis | 1 | 2016 | 1 | 0.510 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 2 | 0.510 |
Why?
|
| Immunocompetence | 1 | 2016 | 31 | 0.500 |
Why?
|
| Drug Storage | 1 | 2016 | 18 | 0.480 |
Why?
|
| Drug Contamination | 1 | 2016 | 35 | 0.480 |
Why?
|
| Syringes | 1 | 2016 | 22 | 0.470 |
Why?
|
| Methotrexate | 1 | 2018 | 337 | 0.470 |
Why?
|
| Security Measures | 1 | 2015 | 5 | 0.470 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 265 | 0.460 |
Why?
|
| Skin Diseases, Genetic | 1 | 2015 | 21 | 0.460 |
Why?
|
| Contracture | 1 | 2015 | 26 | 0.460 |
Why?
|
| Dermatology | 1 | 2015 | 30 | 0.450 |
Why?
|
| Epinephrine | 1 | 2016 | 144 | 0.450 |
Why?
|
| Photography | 1 | 2015 | 80 | 0.440 |
Why?
|
| Crohn Disease | 1 | 2018 | 292 | 0.440 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 121 | 0.440 |
Why?
|
| Models, Anatomic | 1 | 2015 | 107 | 0.410 |
Why?
|
| Skin Diseases | 1 | 2015 | 141 | 0.410 |
Why?
|
| Cyanoacrylates | 1 | 2013 | 12 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 39 | 0.410 |
Why?
|
| Tissue Adhesives | 1 | 2013 | 39 | 0.410 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 92 | 0.400 |
Why?
|
| Eyelid Neoplasms | 1 | 2014 | 29 | 0.400 |
Why?
|
| Nails | 1 | 2013 | 22 | 0.400 |
Why?
|
| Ear Neoplasms | 1 | 2013 | 14 | 0.380 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 5 | 0.370 |
Why?
|
| Ointments | 1 | 2012 | 13 | 0.370 |
Why?
|
| Zinc Oxide | 1 | 2012 | 13 | 0.370 |
Why?
|
| Humans | 30 | 2024 | 130854 | 0.360 |
Why?
|
| Bowen's Disease | 1 | 2011 | 4 | 0.350 |
Why?
|
| Aged | 11 | 2024 | 20970 | 0.340 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 69 | 0.330 |
Why?
|
| Postoperative Care | 1 | 2013 | 297 | 0.330 |
Why?
|
| Explosive Agents | 1 | 2010 | 1 | 0.330 |
Why?
|
| Clinical Competence | 1 | 2018 | 1055 | 0.330 |
Why?
|
| Ochronosis | 1 | 2010 | 4 | 0.330 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 4017 | 0.330 |
Why?
|
| Metals | 1 | 2010 | 67 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 637 | 0.270 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 82 | 0.260 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6797 | 0.260 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 193 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17673 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2564 | 0.240 |
Why?
|
| Male | 13 | 2024 | 64763 | 0.230 |
Why?
|
| Biopsy | 2 | 2019 | 1243 | 0.220 |
Why?
|
| Wound Healing | 2 | 2023 | 481 | 0.220 |
Why?
|
| Female | 13 | 2024 | 70550 | 0.210 |
Why?
|
| Population Health | 1 | 2024 | 35 | 0.200 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2024 | 51 | 0.200 |
Why?
|
| Nasolabial Fold | 1 | 2022 | 1 | 0.190 |
Why?
|
| Middle Aged | 7 | 2024 | 28511 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2023 | 175 | 0.170 |
Why?
|
| Melanoma | 2 | 2024 | 925 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 459 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12913 | 0.160 |
Why?
|
| Chin | 1 | 2019 | 4 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1892 | 0.150 |
Why?
|
| Roman World | 1 | 2018 | 2 | 0.140 |
Why?
|
| Greece, Ancient | 1 | 2018 | 9 | 0.140 |
Why?
|
| History, Medieval | 1 | 2018 | 26 | 0.140 |
Why?
|
| History, Ancient | 1 | 2018 | 53 | 0.140 |
Why?
|
| United States | 2 | 2024 | 11865 | 0.140 |
Why?
|
| History, 19th Century | 1 | 2018 | 111 | 0.140 |
Why?
|
| Granuloma | 1 | 2018 | 60 | 0.140 |
Why?
|
| India | 1 | 2018 | 244 | 0.130 |
Why?
|
| Adult | 5 | 2024 | 31238 | 0.130 |
Why?
|
| Europe | 1 | 2018 | 366 | 0.130 |
Why?
|
| Physical Examination | 1 | 2018 | 160 | 0.130 |
Why?
|
| Adolescent | 3 | 2024 | 20818 | 0.130 |
Why?
|
| Econazole | 1 | 2016 | 2 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 229 | 0.130 |
Why?
|
| Itraconazole | 1 | 2016 | 23 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 360 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 119 | 0.120 |
Why?
|
| Incidence | 1 | 2024 | 3336 | 0.120 |
Why?
|
| Buffers | 1 | 2016 | 27 | 0.120 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 85 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2016 | 98 | 0.120 |
Why?
|
| Skin Aging | 1 | 2015 | 11 | 0.120 |
Why?
|
| Vitamin A | 1 | 2015 | 57 | 0.110 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 88 | 0.110 |
Why?
|
| Hip Joint | 1 | 2015 | 50 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 138 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2016 | 273 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 200 | 0.110 |
Why?
|
| Steroids | 1 | 2015 | 170 | 0.110 |
Why?
|
| Eccrine Glands | 1 | 2014 | 2 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2024 | 3694 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2014 | 28 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2016 | 294 | 0.100 |
Why?
|
| Hair Follicle | 1 | 2014 | 31 | 0.100 |
Why?
|
| Risk Factors | 2 | 2024 | 10978 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2015 | 836 | 0.100 |
Why?
|
| Pressure | 1 | 2013 | 122 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 226 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2012 | 63 | 0.090 |
Why?
|
| Fibrosis | 1 | 2014 | 421 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2012 | 133 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 632 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 330 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2924 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1612 | 0.080 |
Why?
|
| Cytoplasmic Granules | 1 | 2010 | 51 | 0.080 |
Why?
|
| Child | 2 | 2024 | 26215 | 0.080 |
Why?
|
| Young Adult | 1 | 2024 | 10040 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3807 | 0.070 |
Why?
|
| Aging | 1 | 2015 | 1257 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1478 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6217 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1170 | 0.050 |
Why?
|
| Anesthesia, Local | 1 | 2024 | 40 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2024 | 352 | 0.050 |
Why?
|
| Sutures | 1 | 2023 | 62 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1639 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3393 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 18 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 16 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 77 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 397 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6448 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 454 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1587 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 18267 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 33981 | 0.010 |
Why?
|